
10 mg · 20 mg · 30 mg · 50 mg
Retatrutide
Investigational peptide targeting GIP, GLP-1 and glucagon receptors. Studied in clinical trials on body weight and glycemic control.

For research use only
Blend of GHK-Cu, BPC-157, TB-500 and KPV. Studies on the individual components do not evaluate the blend.
Composition: GHK-Cu 50 mg · BPC-157 10 mg · TB-500 10 mg · KPV 10 mg
Preclinical research on individual components.
These studies do not evaluate the KLOW blend.
KLOW is a multi-peptide research blend that combines four widely studied compounds: GHK-Cu (50 mg), BPC-157 (10 mg), TB-500, a fragment related to thymosin beta-4 (10 mg), and KPV, a tripeptide derived from α-MSH (10 mg).
Its components have been studied in preclinical models of tissue-repair signaling, extracellular-matrix activity, inflammatory pathways, angiogenesis and connective-tissue response. The blend as a whole has not been evaluated in published studies; the references below relate to the individual components.
Supplied as a 100 mg vial for laboratory research.
Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests
J Cosmet Dermatol, 2023 · PMID 37062921
View on PubMedPentadecapeptide BPC 157 is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system
J Pharmacol Sci, 2008 · PMID 18818478
View on PubMedPepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Gastroenterology, 2008 · PMID 18061177
View on PubMed
10 mg · 20 mg · 30 mg · 50 mg
Investigational peptide targeting GIP, GLP-1 and glucagon receptors. Studied in clinical trials on body weight and glycemic control.

10 mg · 20 mg
GHRH analog studied in GH/IGF-1 signaling and visceral fat, including trials in people with HIV and altered fat distribution.
Out of stock20 mg
Synthetic peptide studied mainly in preclinical models of tissue repair, intestinal wound healing and inflammatory responses.
$85
per vialIn stock

10 mg · 20 mg · 30 mg · 50 mg
Investigational peptide targeting GIP, GLP-1 and glucagon receptors. Studied in clinical trials on body weight and glycemic control.

10 mg · 20 mg
GHRH analog studied in GH/IGF-1 signaling and visceral fat, including trials in people with HIV and altered fat distribution.
Out of stock20 mg
Synthetic peptide studied mainly in preclinical models of tissue repair, intestinal wound healing and inflammatory responses.